Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer

Abstract excerpt

Colorectal cancer (CRC) is one of the most common and recurrent types of cancer, with high mortality rates. Several clinical trials and meta-analyses have determined that the use of pharmacological inhibitors of cyclooxygenase 2 (COX-2), the enzyme that catalyses the rate-limiting step in the synthesis of prostaglandins (PG) from arachidonic acid, can reduce the incidence of CRC as well as the risk of recurrence...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Estrogen and related hormone effects
• Share to Inflammatory mediators and NSAID effects